Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo de Braud

Showing results (161-170 of 497) with videos related to

Pageof 50
Sort By:
Cancer Treatment Reviews|December 7, 2010
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomasNicola Fazio, Saverio Cinieri, Katia Lorizzo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 16, 2011
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutationsTommaso De Pas, Francesca Toffalorio, Michela Manzotti, et al.
Case Reports in Oncology|October 11, 2016
Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-UpClaudio Vernieri, Daniela Femia, Sara Pusceddu, et al.
Oncotarget|March 7, 2015
A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classificationMatteo Dugo, Gabriella Nicolini, Gabrina Tragni, et al.
Cancer Letters|May 7, 2021
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancerFrancesca Ligorio, Ilaria Pellegrini, Lorenzo Castagnoli, et al.
Journal of Clinical Medicine|April 2, 2020
Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?Alessia Mennitto, Veronica Huber, Raffaele Ratta, et al.
Future Oncology (London, England)|February 19, 2016
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetesSara Pusceddu, Roberto Buzzoni, Claudio Vernieri, et al.
Breast (Edinburgh, Scotland)|May 18, 2018
Dynamics of the hazard for distant metastases after ipsilateral breast tumor recurrence according to estrogen receptor status: An analysis of 2851 patientsMassimiliano Gennaro, Serena Di Cosimo, Ilaria Ardoino, et al.
Oncotarget|September 24, 2017
Concomitant <i>EML4-ALK</i> rearrangement and <i>EGFR</i> mutation in non-small cell lung cancer patients: a literature review of 100 casesGiuseppe Lo Russo, Martina Imbimbo, Giulia Corrao, et al.
European Journal of Internal Medicine|February 20, 2025
Assessment of cardiovascular, thromboembolic and cancer risk in patients eligible for treatment with Janus Kinase inhibitors: The JAK-ERA multidisciplinary consensusLorenzo Dagna, Alessia Alunno, Nicola Farina, et al.
Pageof 50

Showing results (161-170 of 497) with videos related to

Sort By:
Pageof 50
Cancer Treatment Reviews|December 7, 2010
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomasNicola Fazio, Saverio Cinieri, Katia Lorizzo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 16, 2011
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutationsTommaso De Pas, Francesca Toffalorio, Michela Manzotti, et al.
Case Reports in Oncology|October 11, 2016
Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-UpClaudio Vernieri, Daniela Femia, Sara Pusceddu, et al.
Oncotarget|March 7, 2015
A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classificationMatteo Dugo, Gabriella Nicolini, Gabrina Tragni, et al.
Cancer Letters|May 7, 2021
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancerFrancesca Ligorio, Ilaria Pellegrini, Lorenzo Castagnoli, et al.
Journal of Clinical Medicine|April 2, 2020
Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?Alessia Mennitto, Veronica Huber, Raffaele Ratta, et al.
Future Oncology (London, England)|February 19, 2016
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetesSara Pusceddu, Roberto Buzzoni, Claudio Vernieri, et al.
Breast (Edinburgh, Scotland)|May 18, 2018
Dynamics of the hazard for distant metastases after ipsilateral breast tumor recurrence according to estrogen receptor status: An analysis of 2851 patientsMassimiliano Gennaro, Serena Di Cosimo, Ilaria Ardoino, et al.
Oncotarget|September 24, 2017
Concomitant <i>EML4-ALK</i> rearrangement and <i>EGFR</i> mutation in non-small cell lung cancer patients: a literature review of 100 casesGiuseppe Lo Russo, Martina Imbimbo, Giulia Corrao, et al.
European Journal of Internal Medicine|February 20, 2025
Assessment of cardiovascular, thromboembolic and cancer risk in patients eligible for treatment with Janus Kinase inhibitors: The JAK-ERA multidisciplinary consensusLorenzo Dagna, Alessia Alunno, Nicola Farina, et al.
Pageof 50